Cepheid launches new cervical cancer test


The European launch of the 60-minute Xpert HPV test is underway. The IVD molecular diagnostic assay runs on Cepheid's (CPHD) GeneXpert System.

The test targets the E6 and E7 oncogenes of 14 cancer-related HPV types while specifically detecting the high-risk types 16 and 18/45.

HPV types 16 and 18 are associated with 71% of cervical cancer cases while type 45 is tied to 6% of additional cases.

Consensus estimates for Q1 and Q2 are a loss of $0.17/share on revenues of $105M and a loss of $0.06/share on revenues of $111M, respectively.

Consensus estimates for 2014 and 2015 are a loss of $0.24/share on revenues of $457.6M and earnings of $0.06/share on revenues of $533.2M, respectively.

348 mutual funds have positions, down from 377 a year earlier.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs